

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|---|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Aboriginal Health and Medical Research Council NSW | Supporting People With Cancer - Develop locally led Aboriginal cancer networks to support local communities affected by cancer. | 30/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$132,000.00 | CA-G1516/06 | Cancer Australia | Susan Hanson |
| Australasian Gastro-Intestinal Trials Group (AGITG) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,380,000.00 | CA-A1213/80 | Cancer Australia | Gayle Jones |
| Australasian Leukaemia and Lymphoma Group (ALLG) | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,518,000.00 | CA-A1213/82 | Cancer Australia | Gayle Jones |
| Australasian Lung Cancer Trials Group (ALTG) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,380,000.00 | CA-A1213/73 | Cancer Australia | Gayle Jones |
| Australasian Sarcoma Study Group (ASSG) through University of Melbourne | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,379,998.00 | CA-A1213/74 | Cancer Australia | Gayle Jones |
| Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) through Newcastle Innovation Ltd | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,517,938.00 | CA-A1213/77 | Cancer Australia | Gayle Jones |
| Australia New Zealand Gynaecological Oncology Group (ANZGOG) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,380,000.00 | CA-A1213/79 | Cancer Australia | Gayle Jones |
| Australia and New Zealand Melanoma Trials Group (ANZMTG) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,380,000.00 | CA-A1213/83 | Cancer Australia | Gayle Jones |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|---|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) through Monash University | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,379,173.00 | CA-A1213/81 | Cancer Australia | Gayle Jones |
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,380,000.00 | CA-A1213/78 | Cancer Australia | Gayle Jones |
| Australian National University | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency. Appl ID 1045198 | 01/03/2013 | 31/05/2016 | N | N | N | N | N | N | \$582,911.00 | CA-A1213/43 | Cancer Australia | Paul Jackson |
| Australian National University | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Novel combination therapies targeting the ribosome to treat prostate cancer (PC). App. 1085456 | 01/05/2015 | 30/07/2018 | N | N | N | N | N | N | \$599,492.00 | CA-G1415/54 | Cancer Australia | Paul Jackson |
| Breast Cancer Network Australia | Supporting Women in Rural Areas Diagnosed with Breast Cancer (SWRADBC) Program | 01/08/2014 | 30/06/2017 | N | N | N | N | N | N | \$2,619,100.00 | CA-G1415/35 | Cancer Australia | Donna Maroney |
| Breast Cancer Network Australia | Supporting People With Cancer - Develop and disseminate evidence-based, culturally appropriate and in-language resources for Greek and Chinese women affected by secondary breast cancer. | 30/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$131,552.30 | CA-G1516/03 | Cancer Australia | Susan Hanson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|--|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Cancer Council Australia | Supporting People With Cancer - Develop a culturally specific and accessible web-based resource to meet the identified needs of specific CALD communities affected by cancer. | 30/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$132,000.00 | CA-G1516/04 | Cancer Australia | Susan Hanson |
| Cancer Council NSW | Supporting People With Cancer - Develop and implement online, audio-visual webinar information sessions in Mandarin and Cantonese to address the unmet needs of people in the Chinese community who are affected by cancer; and compile existing supportive care services and resources available to the Chinese community. | 09/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$122,100.00 | CA-G1516/07 | Cancer Australia | Susan Hanson |
| Cancer Council QLD | Supporting People With Cancer - Design and deliver evidence-based cancer control courses for Aboriginal and Torres Strait Islander health workers and build local cancer support networks for Aboriginal and Torres Strait Islander people affected by cancer living in regional and rural Queensland. | 30/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$132,000.00 | CA-G1516/05 | Cancer Australia | Susan Hanson |
| Cooperative Trials Group for Neuro-Oncology (COGNO) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,379,859.00 | CA-A1213/76 | Cancer Australia | Gayle Jones |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|--------------------------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Curtin University of Technology | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study. App.1006458. | 01/07/2011 | 01/03/2016 | N | N | N | N | N | N | \$220,993.30 | CA-A1011/41 | Cancer Australia | Paul Jackson |
| Edith Cowan University | 2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits? App1029901 | 01/03/2012 | 31/03/2016 | N | N | N | N | N | N | \$163,634.55 | CA-A1112/12 | Cancer Australia | Paul Jackson |
| Garvan Institute of Medical Research | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): From functional genomics to precision medicine: The therapeutic potential of targeting Rho/ROCK signalling in pancreatic cancer. App1065022 | 21/02/2014 | 20/05/2017 | N | N | N | N | N | N | \$599,997.00 | CA-A1314/04 | Cancer Australia | Paul Jackson |
| Lung Foundation Australia | Supporting People With Cancer - Establish a new Nurse-Led Lung Cancer Support Service to provide clinically-based, patient-centred support for people affected by lung cancer and mesothelioma, including those in regional and rural locations. | 04/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$132,000.00 | CA-G1516/02 | Cancer Australia | Susan Hanson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|---|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Metro South Hospital and Health Service via the Princess Alexandra Hospital | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin: App ID 551200 | 31/01/2009 | 31/10/2016 | N | N | N | N | N | N | \$101,750.00 | CA-A0809/06 | Cancer Australia | Paul Jackson |
| Metro South Hospital and Health Service via the Princess Alexandra Hospital | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer not suitable for Radical Chemo-therapy. App1030265 | 01/05/2012 | 31/07/2018 | N | N | N | N | N | N | \$327,214.80 | CA-A1112/20 | Cancer Australia | Paul Jackson |
| Monash University | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Defining Epigenetic Changes in Prostate Cancer Stroma. Appl ID 1044458 | 31/03/2013 | 30/06/2016 | N | N | N | N | N | N | \$597,987.00 | CA-A1213/60 | Cancer Australia | Paul Jackson |
| Monash University | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): An inhalable dendrimer-based delivery platform for the targeted treatment of primary and secondary lung cancers. App1070184 | 01/05/2014 | 30/07/2017 | N | N | N | N | N | N | \$452,383.00 | CA-A1314/11 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|--|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Primary Care Collaborative Clinical trials Group (PC4TG) through University of Melbourne | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,379,786.00 | CA-A1213/71 | Cancer Australia | Gayle Jones |
| Prince Alexandra Hospital | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised Trial of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. App ID: 1060687 | 28/02/2014 | 27/05/2017 | N | N | N | N | N | N | \$335,000.00 | CA-A1314/12 | Cancer Australia | Paul Jackson |
| Psycho-oncology Co-operative Research Group (PoCoG) through University of Sydney | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,378,065.00 | CA-A1213/75 | Cancer Australia | Gayle Jones |
| Queensland University of Technology | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Identification of HNF1B downstream targets as novel cancer therapeutic targets and biomarkers. App. 1086820 | 30/06/2015 | 30/09/2017 | N | N | N | N | N | N | \$100,000.00 | CA-G1415/52 | Cancer Australia | Paul Jackson |
| Queensland University of Technology | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Evaluating combination therapies in FGFR2mutant EC cell lines and patient-derived xenograft models.. App. 1087165 | 01/05/2015 | 30/07/2018 | N | N | N | N | N | N | \$600,000.00 | CA-G1415/56 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|---|--|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| Rare Cancers Australia Ltd | Supporting People With Cancer -Develop a one-stop shop for people affected by rare cancers, including an online directory of more than 200 rare and less common cancer types and a register of cancer specialists and multidisciplinary teams with expertise and interest in rare cancers. | 04/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$132,000.00 | CA-G1516/01 | Cancer Australia | Susan Hanson |
| The University of Western Australia | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Mammographic density as a predictor of breast cancer risk and mortality in Western Australian Aboriginal women. App. 1085750 | 11/05/2015 | 31/03/2017 | N | N | N | N | N | N | \$137,651.00 | CA-G1415/59 | Cancer Australia | Paul Jackson |
| TransTasman Radiation Oncology Group (TROG) | Support for Cancer Clinical Trials Program | 01/07/2013 | 31/08/2016 | N | N | N | N | N | N | \$1,518,000.00 | CA-A1213/72 | Cancer Australia | Gayle Jones |
| University of Adelaide | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Androgen receptor action in the prostate cancer microenvironment | 01/06/2012 | 31/03/2016 | N | N | N | N | N | N | \$316,571.20 | CA-A1112/33 | Cancer Australia | Paul Jackson |
| University of Adelaide | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. Appl ID 1050880. | 01/05/2013 | 31/07/2017 | N | N | N | N | N | N | \$360,977.00 | CA-A1213/28 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|-------------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Adelaide | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mechanism and targeting of castration-resistant prostate cancer. Appl ID 1043482. | 01/04/2013 | 30/06/2016 | N | N | N | N | N | N | \$270,569.00 | CA-A1213/29 | Cancer Australia | Paul Jackson |
| University of Adelaide | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Targeting the androgen receptor in triple negative breast cancer. Appl ID 1043497. | 01/04/2013 | 30/06/2016 | N | N | N | N | N | N | \$196,474.70 | CA-A1213/30 | Cancer Australia | Paul Jackson |
| University of Adelaide | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. App. 1085471 | 01/04/2015 | 01/07/2018 | N | N | N | N | N | N | \$553,483.00 | CA-G1415/53 | Cancer Australia | Paul Jackson |
| University of Melbourne | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma. App 1029585 | 14/03/2012 | 31/03/2016 | N | N | N | N | N | N | \$651,585.00 | CA-A1112/31 | Cancer Australia | Paul Jackson |
| University of Melbourne | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Solving Unknown Primary cancer - SUPER. Appl ID 1048193. | 01/06/2013 | 30/09/2017 | N | N | N | N | N | N | \$599,381.00 | CA-A1213/21 | Cancer Australia | Paul Jackson |
| University of Melbourne | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: High Risk genes for Lobular Breast Cancer. Appl ID 1047347. | 01/03/2013 | 31/05/2016 | N | N | N | N | N | N | \$100,000.00 | CA-A1213/24 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|-------------------------|--|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls – The IMPACT study. App1059423 | 01/05/2014 | 01/08/2017 | N | N | N | N | N | N | \$292,151.00 | CA-A1314/01 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated Radiotherapy in the treatment of transitional cell carcinoma of the Bladder (RAIDER-B). App1063072 | 01/07/2014 | 30/09/2017 | N | N | N | N | N | N | \$280,000.00 | CA-A1314/03 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Maximising benefits and minimising harms in the BreastScreen program: a population health economics modelling approach. App1066771 | 01/04/2014 | 30/06/2017 | N | N | N | N | N | N | \$593,893.00 | CA-A1314/06 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Quantifying genetic risk in sarcoma and translation into health outcomes. App1067094 | 21/03/2014 | 20/06/2017 | N | N | N | N | N | N | \$597,793.00 | CA-A1314/09 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|-------------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Novel Therapies to Treat Brain Metastatic Breast Cancer.App1067045 | 01/05/2014 | 30/07/2017 | N | N | N | N | N | N | \$398,447.00 | CA-A1314/10 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Investigation of molecular imaging and serum biomarkers to identify lung injury and enable individualised radiation therapy for lung cancers. App ID: 1060919 | 01/04/2014 | 30/06/2017 | N | N | N | N | N | N | \$498,012.00 | CA-A1314/13 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A randomised trial of stereotactic radiotherapy versus conventional radiotherapy for stage I non-small cell lung cancer. App ID: 1060822 | 01/06/2014 | 30/08/2017 | N | N | N | N | N | N | \$320,000.00 | CA-A1314/14 | Cancer Australia | Paul Jackson |
| University of Melbourne | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): High risk genes for childhood cancer: using massively parallel sequencing to identify cancer susceptibility. App ID: 1070106 | 30/06/2014 | 30/09/2016 | N | N | N | N | N | N | \$200,000.00 | CA-G1415/33 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|-------------------------|--|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Melbourne | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Investigating the safety and efficacy, quality of life, cost-efficiency and immune potential of high precision lung radiotherapy. App. 1082399 | 01/06/2015 | 31/08/2018 | N | N | N | N | N | N | \$439,418.00 | CA-G1415/63 | Cancer Australia | Paul Jackson |
| University of Melbourne | Supporting People With Cancer - Engage the Vietnamese community to develop culturally-specific resources and a supporting community engagement campaign to raise awareness about cancer symptoms and promote earlier presentation to healthcare in the Vietnamese community. | 12/06/2015 | 30/06/2018 | N | N | N | N | N | N | \$120,000.00 | CA-G1516/08 | Cancer Australia | Susan Hanson |
| University of NSW | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors. App1065428 | 01/05/2014 | 01/08/2017 | N | N | N | N | N | N | \$457,353.00 | CA-A1314/02 | Cancer Australia | Paul Jackson |
| University of NSW | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): MRP4 and MRP3 transporters: potential new targets in ovarian cancer. App ID: 1067110 | 15/06/2014 | 14/09/2017 | N | N | N | N | N | N | \$589,989.00 | CA-A1314/71 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|--------------------------|--|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Queensland | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): The feMMe trial. App. 1078121 | 01/06/2015 | 31/08/2018 | N | N | N | N | N | N | \$540,000.00 | CA-G1415/60 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Randomised Multicentre Phase III Study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib | 31/01/2009 | 31/10/2016 | N | N | N | N | N | N | \$284,900.00 | CA-A0809/34 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial: App 1009485 | 01/03/2011 | 28/05/2016 | N | N | N | N | N | N | \$650,111.00 | CA-A1011/37 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: PORTEC-3 - The role of adjuvant chemotherapy in high-risk endometrial cancer: App 1027151 | 01/02/2012 | 31/03/2016 | N | N | N | N | N | N | \$330,965.80 | CA-A1112/08 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer: App 1032121 | 01/02/2012 | 30/04/2016 | N | N | N | N | N | N | \$139,933.75 | CA-A1112/13 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|----------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial | 17/02/2012 | 16/11/2016 | N | N | N | N | N | N | \$220,000.00 | CA-A1112/24 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. Appl ID 1048035 | 04/03/2013 | 03/06/2016 | N | N | N | N | N | N | \$123,331.00 | CA-A1213/45 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The Use and Impact of High Cost Targeted Cancer Medicines: Theory and Reality. Appl ID 1050648 | 04/03/2013 | 31/03/2017 | N | N | N | N | N | N | \$133,002.00 | CA-A1213/55 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. Appl ID 1041733 | 01/06/2013 | 31/10/2017 | N | N | N | N | N | N | \$252,583.48 | CA-A1213/56 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|----------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation. Appl ID 1046923 | 04/03/2013 | 03/06/2016 | N | N | N | N | N | N | \$184,475.00 | CA-A1213/57 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial. Appl ID 1041651 | 01/06/2013 | 31/05/2017 | N | N | N | N | N | N | \$457,143.17 | CA-A1213/58 | Cancer Australia | Paul Jackson |
| University of Sydney | Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer. Appl ID 1044344 | 04/03/2013 | 03/06/2016 | N | N | N | N | N | N | \$257,241.00 | CA-A1213/59 | Cancer Australia | Paul Jackson |
| University of Sydney | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Hitting the Target: Real-Time Prostate Cancer Radiotherapy. App1064731 | 01/06/2014 | 31/08/2017 | N | N | N | N | N | N | \$171,854.00 | CA-A1314/05 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|----------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Sydney | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): ECHO trial: Exercise during Chemotherapy for Ovarian cancer. App1063509 | 01/04/2014 | 30/06/2017 | N | N | N | N | N | N | \$300,000.00 | CA-A1314/07 | Cancer Australia | Paul Jackson |
| University of Sydney | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial.App1068044 | 01/04/2014 | 30/06/2017 | N | N | N | N | N | N | \$276,811.50 | CA-A1314/08 | Cancer Australia | Paul Jackson |
| University of Sydney | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms: PARAGON. App1063014 | 01/06/2014 | 30/08/2017 | N | N | N | N | N | N | \$546,676.00 | CA-A1314/69 | Cancer Australia | Paul Jackson |
| University of Sydney | 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers. App1067589 | 09/06/2014 | 08/09/2017 | N | N | N | N | N | N | \$119,280.00 | CA-A1314/70 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|----------------------|--|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase III trial of Concurrent & Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. App.1078665 | 28/02/2015 | 27/05/2018 | N | N | N | N | N | N | \$190,213.00 | CA-G1415/39 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS):Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy. App.1079794 | 20/06/2015 | 20/09/2018 | N | N | N | N | N | N | \$297,525.00 | CA-G1415/40 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Reducing Thoracic Imaging Dose and Improving Image Quality in Radiotherapy Treatments. App.1084566 | 30/06/2015 | 29/09/2018 | N | N | N | N | N | N | \$458,459.00 | CA-G1415/41 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS):Real-time Six Degree of Freedom Tumour Motion Management in Cancer Radiotherapy. App.1085360 | 28/02/2015 | 28/02/2019 | N | N | N | N | N | N | \$441,385.00 | CA-G1415/42 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): ANZMTG 01.07 Whole Brain Radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma – a randomised phase III trial. App. 1084046 | 01/05/2015 | 30/07/2018 | N | N | N | N | N | N | \$335,963.00 | CA-G1415/50 | Cancer Australia | Paul Jackson |

**Murray Motion
Reporting for 2015 Calendar Year**

| Grant Participant | Contract Purpose | Activity Start Date (Legacy Start Date for Migrated Agreements) | Activity End Date | Confidentiality Provisions Indicator | Confidentiality Provisions Reasons | Confidentiality Provisions Reason if 'Other' | Confidentiality Outputs Indicator | Confidentiality Outputs Reason | Confidentiality Outputs Reason if 'Other' | Total Activity Value Amount (inc GST) | Activity Id | Managing Office | Contract Manager |
|----------------------|---|---|-------------------|--------------------------------------|------------------------------------|--|-----------------------------------|--------------------------------|---|---------------------------------------|-------------|------------------|------------------|
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): ANZMTG 01.12 RADICAL – RADiotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo mALigna (LM). App. 1083221 | 01/05/2015 | 30/07/2018 | N | N | N | N | N | N | \$600,000.00 | CA-G1415/51 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): SPARK: STEREOTACTIC PROSTATE ADAPTIVE RADIOTHERAPY UTILISING KILOVOLTAGE INTRAFRACTION MONITORING. App. 1081534 | 01/06/2015 | 30/08/2018 | N | N | N | N | N | N | \$193,800.00 | CA-G1415/55 | Cancer Australia | Paul Jackson |
| University of Sydney | 2014 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): SPARK: STEREOTACTIC PROSTATE ADAPTIVE RADIOTHERAPY UTILISING KILOVOLTAGE INTRAFRACTION MONITORING. App. 1081534 | 01/06/2015 | 30/08/2018 | N | N | N | N | N | N | \$193,799.00 | CA-G1415/55 | Cancer Australia | Paul Jackson |